C
Christine A. White
Researcher at Biogen Idec
Publications - 79
Citations - 14005
Christine A. White is an academic researcher from Biogen Idec. The author has contributed to research in topics: Rituximab & Radioimmunotherapy. The author has an hindex of 36, co-authored 78 publications receiving 13649 citations. Previous affiliations of Christine A. White include Northwestern University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Peter McLaughlin,Antonio J. Grillo-Lopez,Brian K. Link,Ronald Levy,Myron S. Czuczman,Michael E. Williams,M R Heyman,I. Bence-Bruckler,Christine A. White,Fernando Cabanillas,Vinay K. Jain,A D Ho,John Lister,K Wey,D. Shen,Brian Dallaire +15 more
TL;DR: The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy, and further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.
Journal ArticleDOI
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
David G. Maloney,Antonio J. Grillo-Lopez,Christine A. White,David Bodkin,Russell J. Schilder,James A. Neidhart,Nalini Janakiraman,Kenneth A. Foon,Tina Marie Liles,Brian Dallaire,Ken Wey,Ivor Royston,Thomas A. Davis,Ronald Levy +13 more
TL;DR: Likelihood of tumor response was associated with a follicular histology, with the ability to sustain a high serum level of antibody after the first infusion, and with a longer duration of remission to prior chemotherapy, and IDEC-C2B8 has a better safety profile.
Journal ArticleDOI
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
Thomas E. Witzig,Leo I. Gordon,Fernando Cabanillas,Myron S. Czuczman,Christos Emmanouilides,Robin Joyce,Brad Pohlman,Nancy L. Bartlett,Gregory A. Wiseman,Norman Padre,Antonio J. Grillo-Lopez,Pratik S. Multani,Christine A. White +12 more
TL;DR: Radioimmunotherapy with (90)Y ibritumomab tiuxetan is well tolerated and produces statistically and clinically significant higher ORR and CR compared with rituximab alone.
Journal ArticleDOI
Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
Myron S. Czuczman,Antonio J. Grillo-Lopez,Christine A. White,Mansoor N. Saleh,Leo I. Gordon,A. F. LoBuglio,C. Jonas,D. Klippenstein,B. Dallaire,C. Varns +9 more
TL;DR: This is the first report demonstrating the safety and efficacy of Rituxan anti-CD20 chimeric antibody in combination with standard-dose systemic chemotherapy in the treatment of indolent B-cell lymphoma.
Journal ArticleDOI
Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment
Thomas A. Davis,Antonio J. Grillo-Lopez,Christine A. White,Peter McLaughlin,Myron S. Czuczman,Brian K. Link,David G. Maloney,R. Weaver,Jay Rosenberg,Ronald Levy +9 more
TL;DR: In this re-treatment population of patients with low-grade or follicular non-Hodgkin's lymphoma who relapsed after a response to rituximab therapy, safety and efficacy were not apparently different from those after initial ritUXimab exposure.